A local anaesthetic in its lowest concentration will block
Rationale:
A local anaesthetic in its lowest concentration will block preganglionic sympathetic fibers. This occurs because preganglionic sympathetic fibers are smaller and have a higher susceptibility to local anaesthetics due to their thin, lightly myelinated structure, making them the first to be affected. Larger, more heavily myelinated somatic fibers require higher concentrations for blockade.
A: Somatic motor Larger diameter and heavier myelination make somatic motor fibers less sensitive, requiring higher anaesthetic concentrations to inhibit conduction, so they are not blocked at the lowest concentration.
B: Somatic sensory Somatic sensory fibers, especially larger ones, have greater resistance to local anaesthetics, meaning low concentrations do not effectively block these sensations initially.
D: All of the above Local anaesthetics at low concentrations selectively block preganglionic sympathetic fibers; somatic motor and sensory fibers require higher concentrations, so simultaneous blockage of all three does not occur.
IV administration of phenytoin in status epilepticus carries the danger of
Rationale:
IV administration of phenytoin in status epilepticus carries the danger of arrhythmia. Phenytoin affects cardiac conduction by blocking sodium channels, which can cause hypotension and various arrhythmias, especially if infused rapidly. This risk necessitates careful monitoring of cardiac function during administration, particularly in patients with pre-existing heart conditions or electrolyte imbalances that exacerbate arrhythmogenic potential.
B: Cerebellar atrophy results from chronic toxicity, not acute IV administration. This degenerative condition develops over prolonged exposure rather than during emergency seizure treatment with phenytoin. It is unrelated to immediate intravenous dosing complications.
C: Renal failure is not a recognized acute adverse effect of IV phenytoin. Phenytoin metabolism primarily involves hepatic pathways, and nephrotoxicity is uncommon during short-term intravenous administration in status epilepticus.
D: Jaundice is generally linked to chronic hepatic dysfunction or hypersensitivity reactions, not rapid IV phenytoin use. Immediate administration risks focus on cardiovascular effects rather than liver enzyme disturbances causing jaundice.
Quinidine is contraindicated in
Rationale:
Quinidine is contraindicated in Digoxin toxicity.
Quinidine can increase serum digoxin levels by reducing its clearance, potentially leading to toxic effects such as arrhythmias. This interaction exacerbates digoxin toxicity risks, making quinidine unsafe for patients experiencing digoxin overdose or toxicity. Careful consideration must be given to avoid worsening cardiac complications caused by elevated digoxin concentrations when quinidine is involved.
A: Atrial flutter Quinidine is not contraindicated in atrial flutter; it is often used to manage this arrhythmia by slowing conduction and controlling ventricular response.
B: PSVT Quinidine does not contraindicate paroxysmal supraventricular tachycardia treatment; alternative antiarrhythmics are preferred, but quinidine’s use is not explicitly forbidden in this condition.
C: Atrial fibrillation Quinidine is sometimes employed to treat atrial fibrillation, especially for rhythm control, so it is not contraindicated in this arrhythmia.
Which of the following is an ergot derivative used in Parkinson's disease as a dopamine agonist?
Rationale:
Bromocriptine is an ergot derivative used in Parkinson's disease as a dopamine agonist. Bromocriptine mimics dopamine by stimulating dopamine receptors, helping alleviate motor symptoms in Parkinson's patients. Being an ergot alkaloid, it has a distinct chemical structure that differentiates it from other treatments, which primarily focus on dopamine replacement or inhibition of dopamine breakdown, making it effective in managing the disease.
A: Levodopa converts to dopamine in the brain but is not an ergot derivative; it acts as a precursor rather than directly stimulating dopamine receptors.
C: Amantadine is an antiviral with anti-Parkinsonian effects, mainly enhancing dopamine release and blocking receptors, but it is unrelated to ergot alkaloids.
D: Selegiline inhibits monoamine oxidase B to prevent dopamine degradation; it does not have an ergot structure nor directly agonize dopamine receptors.
The tricyclic antidepressant drugs produce their effect by
Rationale:
Tricyclic antidepressant drugs produce their effect by causing inhibition of noradrenaline and 5-HT re-uptake by the pre-synaptic neuronal membrane. This mechanism increases the synaptic concentrations of both neurotransmitters, enhancing their action in the CNS. The combined re-uptake inhibition leads to improved mood and alleviation of depressive symptoms, which single neurotransmitter targeting cannot achieve as effectively.
A: Increasing the synaptic concentration of noradrenaline in the CNS only addresses one neurotransmitter, neglecting 5-HT, which is also crucial for the antidepressant effect of tricyclic drugs.
B: Increasing the synaptic concentration of 5-HT in the CNS focuses solely on serotonin, but tricyclic antidepressants also target noradrenaline, making this explanation incomplete.
C: By causing inhibition of noradrenaline and 5-HT re-uptake by the pre-synaptic neuronal membrane describes the precise mechanism, but the question asks for the overall effect, which encompasses both neurotransmitters.
When an amide is acted upon by an amidase
Rationale:
An amide acted upon by an amidase produces an alcohol and an amine. Amidases specifically catalyze the hydrolysis of amide bonds, breaking them into an amine and a carboxylic acid. The acid can further react or be present as its conjugate base, but the primary immediate products are amine and alcohol derivatives depending on the substrate structure.
A: Alcohol and acid is formed does not encompass the amine group generated by amidase activity, which specifically cleaves amides into amines and acids, not alcohols directly.
B: Amine and acid is formed neglects the formation of alcohol, which can be part of the substrate’s structure, especially in ester-amide linked compounds processed by amidase.
D: None of the above dismisses the known enzymatic function of amidase in converting amides into amines and related products, conflicting with established biochemical knowledge.
Plasma lithium levels may become toxic in the presence of all of the following EXCEPT
Rationale:
Plasma lithium levels may become toxic in the presence of pregnancy. Lithium toxicity is typically associated with factors that decrease renal clearance or increase lithium reabsorption, such as thiazides, dehydration, and certain NSAIDs, whereas pregnancy does not inherently alter lithium metabolism or clearance to a degree that causes toxicity.
B: Use of thiazides elevates lithium levels by promoting sodium retention and enhancing lithium reabsorption in renal tubules, significantly increasing toxicity risk.
C: Dehydration concentrates lithium in plasma by reducing renal filtration, leading to elevated lithium levels and higher toxicity potential.
D: Use of some NSAIDs reduces renal prostaglandin synthesis, decreasing lithium clearance and thereby raising plasma lithium concentrations, increasing toxicity risk.
Regarding opioid receptors, which statement is true?
Rationale:
Both µ and delta receptors contribute to respiratory depression. These opioid receptor subtypes modulate respiratory centers in the brainstem, leading to decreased respiratory drive. The µ receptor primarily mediates opioid effects, but delta receptors also influence respiratory function, making their combined action critical in opioid-induced respiratory depression.
A: Fentanyl primarily targets µ receptors, not kappa, producing potent analgesia and respiratory depression. Its effect at kappa receptors is minimal and not responsible for its main clinical actions.
C: Methadone acts mainly on µ receptors to alleviate heroin withdrawal symptoms, not predominantly on delta receptors, which play a lesser role in opioid substitution therapy.
D: Opioid receptors are G-protein coupled receptors, not linked to tyrosine kinase mechanisms, which are characteristic of different receptor families involved in growth and differentiation signaling.
A 58-year-old woman with a history of myasthenia gravis presents to the emergency department complaining of generalized abdominal pain. Her current medications include nifedipine and neostigmine. Her caretaker reports that her bottle of neostigmine is empty but was full earlier in the day. Which of the following findings is likely in this patient?
Rationale:
This patient is likely to have constipation.
Neostigmine is an acetylcholinesterase inhibitor that increases acetylcholine at neuromuscular junctions and autonomic synapses, promoting gastrointestinal motility. Abrupt cessation can reduce parasympathetic stimulation, leading to decreased bowel movements and constipation, especially in a myasthenia gravis patient reliant on this medication for muscle and smooth muscle function.
A: Bronchodilation Reduced acetylcholine decreases parasympathetic tone, leading to bronchoconstriction, not bronchodilation.
C: Dizziness Lack of neostigmine primarily affects muscle strength and autonomic functions, but dizziness is not a typical acute symptom of its withdrawal.
D: Hypotension While acetylcholine influences blood pressure, abrupt neostigmine stoppage more commonly causes muscle weakness rather than significant hypotension.
A 72-year-old woman with Parkinson's disease is taking a medication that increases release of dopamine, blockade of cholinergic receptors, and inhibiting the N-methyl-D-aspartate receptor. This describes which of the following agents?
Rationale:
Amantadine increases dopamine release, blocks cholinergic receptors, and inhibits the N-methyl-D-aspartate (NMDA) receptor. Amantadine’s unique pharmacological profile includes enhancing dopaminergic neurotransmission while providing anticholinergic effects and NMDA receptor antagonism, which helps reduce Parkinsonian symptoms and dyskinesias. This combination distinguishes it from other Parkinson’s medications, making it the agent described in the question.
B: Bromocriptine is a dopamine agonist that directly stimulates dopamine receptors without anticholinergic or NMDA receptor inhibition properties, thus lacking the combined mechanisms described.
C: Pramipexole selectively activates dopamine receptors but does not promote dopamine release, block cholinergic receptors, or inhibit NMDA receptors, differentiating its mode of action.
D: Rotigotine acts as a dopamine agonist delivered via a patch, primarily stimulating dopamine receptors without the additional cholinergic blockade or NMDA antagonism mentioned.
A 45-year-old man with attention-deficit/hyperactivity disorder presents to his primary care physician for evaluation and treatment. Physical examination of the heart, lungs, and abdomen are within normal limits. The patient has begun on atomoxetine. Which of the following underlying disorders must the treating physician be aware of?
Rationale:
Atomoxetine requires caution in patients with bipolar disorder due to the risk of inducing manic or hypomanic episodes. This medication’s noradrenergic effects can destabilize mood, making it crucial for physicians to assess for underlying bipolar disorder before initiating treatment.
A: Anxiety Anxiety does not contraindicate atomoxetine, though it may coexist with ADHD; anxiety symptoms typically do not worsen significantly with this medication.
C: Bleeding disorders Atomoxetine does not primarily affect coagulation or platelet function, so bleeding disorders are not a major concern requiring special caution.
D: Chronic diarrhea Chronic diarrhea is unrelated to atomoxetine’s mechanism or side effect profile and does not necessitate additional monitoring.
A 35-year-old man who is an immigrant has been taking prazepam for anxiety for 10 years. This drug is not available in the United States, so he goes to see a physician about a drug that would be a good replacement. What might happen to this patient if he was unable to replace his prazepam and abruptly quit taking it?
Rationale:
Abruptly quitting prazepam can cause convulsions and hallucinations. Prazepam is a benzodiazepine, and sudden discontinuation after long-term use often leads to withdrawal symptoms such as seizures and perceptual disturbances due to CNS hyperexcitability. This is because benzodiazepines enhance GABAergic inhibition, and stopping them abruptly removes this effect, causing neuronal overactivity and dangerous withdrawal manifestations.
A: Adrenal insufficiency relates to corticosteroid withdrawal, not benzodiazepine cessation, so it does not align with the typical symptoms seen with stopping prazepam abruptly.
C: Fever and muscle rigidity are hallmark signs of neuroleptic malignant syndrome, linked to antipsychotics, not benzodiazepine withdrawal.
D: Myocardial infarction is a cardiovascular event unrelated to benzodiazepine discontinuation and does not describe common withdrawal effects.
A 67-year-old man with hypertension is treated with guanethidine. He has been taking this medication for years. His blood pressure is 130/86 mm Hg. Which of the following adverse effects must this patient be aware of?
Rationale:
Erectile dysfunction is a known adverse effect of guanethidine therapy. Guanethidine depletes norepinephrine from sympathetic nerve endings, leading to decreased sympathetic tone and impaired vasoconstriction, which can result in sexual dysfunction. Chronic use can affect autonomic regulation, causing difficulties in achieving or maintaining an erection, making patients aware of this potential side effect essential in long-term management.
B: Hepatitis is not associated with guanethidine use; it primarily affects sympathetic neurotransmission rather than liver function, so liver inflammation or damage is unrelated to this medication’s pharmacological profile.
C: Hypertension is unlikely here since guanethidine lowers blood pressure by inhibiting norepinephrine release, not increasing it; thus, it does not cause hypertension but treats it effectively.
D: Pheochromocytoma is a rare adrenal tumor causing excess catecholamine release, unrelated to guanethidine’s mechanism or side effects, which suppress sympathetic neurotransmitters rather than stimulate tumor formation.
A 43-year-old woman with a history of fibromyalgia and depression presents to her primary care physician for treatment. She complains of feeling sad and worthless in addition to multiple somatic complaints. Which of the following treatments would be best for this patient?
Rationale:
Duloxetine is the best treatment for this patient. Duloxetine effectively treats both fibromyalgia and depression by inhibiting serotonin and norepinephrine reuptake, addressing mood symptoms and chronic pain simultaneously. This dual action makes it ideal for patients with comorbid fibromyalgia and depressive symptoms, improving overall quality of life by targeting multiple facets of her condition in a single medication.
B: Fluoxetine primarily targets serotonin reuptake and is less effective for chronic pain syndromes like fibromyalgia, making it suboptimal for managing her somatic complaints alongside depression.
C: Mirtazapine mainly enhances noradrenergic and specific serotonergic activity but lacks strong evidence for fibromyalgia pain relief, limiting its utility in this combined presentation.
D: Sertraline, a selective serotonin reuptake inhibitor, does not significantly address neuropathic or musculoskeletal pain typical in fibromyalgia, reducing its effectiveness for this patient's somatic symptoms.
Which of the following drugs acts as a competitive benzodiazepine receptor antagonist:
Rationale:
Flumazenil acts as a competitive benzodiazepine receptor antagonist. Flumazenil selectively binds to benzodiazepine sites on the GABA-A receptor, effectively reversing the sedative effects of benzodiazepines without intrinsic agonist activity. It is commonly used to counteract benzodiazepine overdoses due to this competitive inhibition, restoring normal receptor function by displacing benzodiazepines from their binding sites.
A: Naloxone primarily targets opioid receptors to reverse opioid overdose, lacking affinity for benzodiazepine sites, thus it cannot antagonize benzodiazepine effects competitively.
C: Flurazepam functions as a benzodiazepine agonist, enhancing GABAergic inhibition rather than competing with benzodiazepines at their receptor site.
D: Disulfiram inhibits aldehyde dehydrogenase to deter alcohol consumption and does not interact with benzodiazepine receptors or their competitive binding.
The following is a selective serotonin reuptake inhibitor used in treatment of psychic depression:
Rationale:
Fluoxetine is a selective serotonin reuptake inhibitor used in the treatment of psychic depression. It specifically targets serotonin reuptake, enhancing serotonin levels in the brain, which alleviates depressive symptoms. Unlike other antidepressants, fluoxetine’s mechanism focuses on serotonin without significantly affecting norepinephrine or dopamine pathways, making it a preferred SSRI for managing depressive disorders efficiently and with fewer side effects.
A: Imipramine primarily functions as a tricyclic antidepressant affecting both norepinephrine and serotonin but is not classified as an SSRI, thus differing in its mechanism from selective serotonin reuptake inhibitors.
B: Amitriptyline acts mainly as a tricyclic antidepressant influencing multiple neurotransmitters, including norepinephrine and serotonin, but lacks the selective serotonin reuptake inhibition characteristic of SSRIs.
D: Maprotiline is a tetracyclic antidepressant that mainly inhibits norepinephrine reuptake and does not selectively target serotonin, distinguishing it from SSRIs like fluoxetine.
Side effects of benzodiazepines include the following EXCEPT:
Rationale:
Side effects of benzodiazepines include all options except convulsions. Benzodiazepines are known to cause tolerance, dependence, amnesia, and daytime sedation due to their central nervous system depressant effects. However, they are primarily used as anticonvulsants and muscle relaxants, making convulsions an unlikely side effect. Their pharmacological action generally prevents seizures rather than inducing them.
A: Tolerance and dependence develop with prolonged benzodiazepine use because the body adapts to the drug’s effects, requiring higher doses for the same impact and leading to withdrawal symptoms upon cessation.
C: Amnesia occurs as benzodiazepines interfere with memory consolidation, particularly affecting short-term memory, which can result in difficulties forming new memories during drug administration.
D: Day-time sedation results from benzodiazepines’ depressant influence on the central nervous system, causing drowsiness, impaired alertness, and reduced cognitive and motor performance during waking hours.
Aspirin has all the following effects EXCEPT:
Rationale:
Aspirin does not have anti-psychotic effects. Aspirin primarily functions by inhibiting cyclooxygenase enzymes, reducing prostaglandin synthesis, which provides antipyretic, anti-inflammatory, and analgesic effects. It effectively lowers fever, decreases inflammation, and alleviates pain but has no impact on neurotransmitter systems involved in psychosis or psychiatric disorders, thus lacking anti-psychotic properties.
A: Antipyretic Aspirin reduces fever by inhibiting prostaglandin production in the hypothalamus, which resets the body’s temperature regulation. This effect is well-established and widely utilized in clinical settings.
B: Anti-inflammatory Aspirin’s inhibition of cyclooxygenase leads to decreased formation of inflammatory mediators, effectively reducing swelling and inflammation in tissues, a primary therapeutic use of the drug.
C: Analgesic Aspirin alleviates pain by blocking the synthesis of prostaglandins responsible for sensitizing nerve endings. This analgesic property makes it useful for mild to moderate pain relief.
Probenecid is effective in the treatment of gout because it:
Rationale:
Probenecid acts to promote excretion of urate (uric acid).
Probenecid enhances renal excretion of uric acid by inhibiting its reabsorption in the proximal tubules, thereby lowering serum urate levels and preventing crystal deposition in joints. This uricosuric effect directly addresses hyperuricemia, the underlying cause of gout, making it effective for reducing acute and chronic gout symptoms.
A: Prevents mobilization of leukocytes release of inflammatory mediators This option describes anti-inflammatory effects unrelated to probenecid’s mechanism, which targets urate elimination rather than leukocyte activity or mediator release.
B: Inhibits xanthine oxidase Xanthine oxidase inhibition is characteristic of drugs like allopurinol, not probenecid, which primarily facilitates urate excretion rather than decreasing urate production.
D: Blocks de novo synthesis of urate (uric acid) Blocking urate synthesis involves interfering with purine metabolism enzymes, a mechanism distinct from probenecid’s promotion of urate clearance through the kidneys.
A 55-year-old woman undergoes surgery. She receives several drugs for preoperative care and intraoperative. Toward the end of the procedure she develops hyperthermia, hypertension, hyperkalemia, muscle rigidity, and metabolic acidosis. Which of the following drugs is most likely to have participated in this reaction?
Rationale:
Halothane is most likely to have participated in this reaction. Malignant hyperthermia is a rare, life-threatening condition triggered by volatile anesthetics like halothane, characterized by hyperthermia, muscle rigidity, hyperkalemia, and metabolic acidosis. These signs align closely with halothane’s known adverse effects in susceptible individuals during anesthesia, confirming its role in this clinical scenario.
A: Fentanyl Opioids like fentanyl typically cause respiratory depression and sedation, not hyperthermia or muscle rigidity. They do not trigger malignant hyperthermia or significant metabolic acidosis, making fentanyl an unlikely cause here.
C: Ketamine Ketamine is a dissociative anesthetic inducing sympathetic stimulation but does not cause malignant hyperthermia. Its adverse effects mostly involve increased heart rate and blood pressure, not the hyperkalemia or rigidity seen in this case.
D: Midazolam Midazolam is a benzodiazepine producing sedation and anxiolysis without causing hyperthermia or muscle rigidity. It lacks any association with malignant hyperthermia or the metabolic disturbances presented in this patient.
Minipill hormonal contraception is composed of:
Rationale:
Minipill hormonal contraception is composed of low dose progestin alone.
This option accurately describes the minipill, which contains only progestin at a low dose without estrogen. It works primarily by thickening cervical mucus and altering the endometrium, reducing fertility while avoiding estrogen-related side effects, making it suitable for women who cannot take estrogen-containing contraceptives.
A: High dose estrogen + high dose progestin describes combined pills, not the minipill, which lacks estrogen entirely and uses only low dose progestin.
B: Low dose estrogen + low dose progestin refers to combination oral contraceptives, differing from the minipill’s progestin-only formulation.
C: Low dose estrogen alone is not used in contraceptive pills; estrogen-only pills are not standard contraceptive options and do not describe the minipill.
Possible treatment of hypoglycemia should NOT include:
Rationale:
Possible treatment of hypoglycemia should NOT include insulin.
Insulin lowers blood glucose levels, which would worsen hypoglycemia instead of alleviating it. Treatments for hypoglycemia aim to increase blood sugar rapidly, so administering insulin contradicts this goal and can lead to dangerous declines in glucose, making it unsuitable and harmful in hypoglycemic management.
B: Glucagon stimulates the liver to release stored glucose, effectively raising blood sugar levels and counteracting hypoglycemia, making it a suitable treatment option.
C: Glucose provides immediate sugar to the bloodstream, directly increasing blood glucose levels and resolving hypoglycemia promptly.
D: Fruit juice contains natural sugars that are quickly absorbed, offering an accessible and effective remedy for raising low blood glucose during hypoglycemia.
The mechanism by which thiocyanate reduces synthesis of thyroid hormones is by inhibition of which of the following?
Rationale:
Thiocyanate reduces synthesis of thyroid hormones by inhibition of iodide transport.
This inhibition prevents iodide from entering thyroid follicular cells, a crucial step for hormone production. Without iodide transport, iodide cannot be oxidized or incorporated into thyroglobulin, thereby decreasing thyroid hormone synthesis. Thiocyanate competes with iodide at the sodium-iodide symporter, directly reducing the available substrate for hormone formation in the thyroid gland.
A: Iodine oxidation This process occurs after iodide transport, so blocking oxidation alone does not explain thiocyanate’s primary mechanism. Thiocyanate specifically targets iodide uptake, not the enzymatic oxidation step.
C: Inhibiting the secretion of TSH Thiocyanate does not affect the pituitary gland’s TSH release; its action is localized at the thyroid gland’s iodide transport, making TSH secretion irrelevant here.
D: TSH biosynthesis Thiocyanate does not interfere with the production of TSH in the pituitary. The compound’s effect is confined to iodide handling within the thyroid, not hormone synthesis upstream.
For patients who have been on long-term therapy with a glucocorticoid and who now wish to discontinue the drug, gradual tapering of the glucocorticoid is needed to allow recovery of:
Rationale:
Gradual tapering of glucocorticoids is needed to allow recovery of the hypothalamic-pituitary-adrenal system.
Long-term glucocorticoid therapy suppresses the hypothalamic-pituitary-adrenal axis through negative feedback, reducing endogenous cortisol production. Tapering prevents adrenal insufficiency by gradually restoring normal adrenal function, allowing the axis to resume hormonal regulation and maintain physiological cortisol levels essential for stress response and metabolic balance.
B: Hematopoiesis in the bone marrow is unrelated to glucocorticoid tapering; bone marrow function is not directly suppressed by glucocorticoid withdrawal.
C: Vasopressin control of water excretion is independent of glucocorticoid effects and does not require glucocorticoid tapering for recovery.
D: Normal osteoblast function is affected by glucocorticoids but does not recover through tapering related to adrenal axis restoration.
Plasma lithium levels may become toxic in the presence of all of the following EXCEPT
Rationale:
Plasma lithium levels may become toxic in the presence of pregnancy.
Pregnancy is not associated with increased lithium toxicity because physiological changes typically enhance lithium clearance, reducing plasma levels. In contrast, thiazides, dehydration, and certain NSAIDs reduce lithium excretion, thereby elevating plasma concentrations and the risk of toxicity. This distinction highlights the unique pharmacokinetic behavior of lithium during pregnancy versus other conditions.
B: Use of thiazides reduces lithium renal clearance by promoting sodium loss, which increases lithium reabsorption in the proximal tubule, raising plasma lithium levels and enhancing toxicity risk significantly.
C: Dehydration concentrates lithium in plasma by decreasing renal perfusion and glomerular filtration rate, impairing lithium elimination and predisposing patients to toxic accumulation.
D: Some NSAIDs inhibit renal prostaglandin synthesis, decreasing lithium clearance and increasing plasma concentrations, thereby heightening the likelihood of lithium toxicity during concurrent use.
Regarding opioid receptors, which statement is true?
Rationale:
Both µ and delta receptors contribute to respiratory depression. Opioid receptors, particularly the µ subtype, mediate respiratory depression, but delta receptors also play a role in modulating respiratory function, making this statement accurate. Understanding the involvement of multiple receptor types is crucial for comprehending opioid effects on respiration and potential risks during opioid therapy or overdose situations.
A: Fentanyl works predominantly at the kappa receptors This is inaccurate because fentanyl primarily targets µ opioid receptors, producing potent analgesic and respiratory depressive effects rather than acting mainly on kappa receptors.
C: Methadone is used for heroin withdrawal because its actions are predominantly at the delta receptors Methadone primarily acts on µ receptors, not delta receptors, which explains its efficacy in managing heroin withdrawal symptoms through sustained µ receptor activation.
D: Opioid receptors are coupled to a tyrosine kinase mechanism of action Opioid receptors signal via G-protein-coupled mechanisms, not tyrosine kinase pathways, distinguishing their intracellular signaling from receptor types that use tyrosine kinase cascades.
A 58-year-old woman with a history of myasthenia gravis presents to the emergency department complaining of generalized abdominal pain. Her current medications include nifedipine and neostigmine. Her caretaker reports that her bottle of neostigmine is empty but was full earlier in the day. Which of the following findings is likely in this patient?
Rationale:
This patient is likely to experience constipation.
Neostigmine is a cholinesterase inhibitor that increases parasympathetic activity, promoting gastrointestinal motility. An empty neostigmine bottle suggests missed doses, leading to decreased parasympathetic stimulation and resulting in reduced bowel movements, hence constipation. This symptom aligns with the patient’s history and medication discontinuation, causing impaired autonomic regulation of the digestive tract.
A: Bronchodilation Bronchodilation results from sympathetic activation, not decreased parasympathetic activity. Missing neostigmine reduces parasympathetic tone, causing bronchoconstriction rather than bronchodilation.
C: Dizziness Dizziness is nonspecific and unrelated to neostigmine withdrawal or myasthenia gravis exacerbation; it does not directly result from altered parasympathetic stimulation.
D: Hypotension Hypotension is not a typical presentation following missed neostigmine; parasympathetic withdrawal usually does not cause low blood pressure in this context.
A 72-year-old woman with Parkinson's disease is taking a medication that increases release of dopamine, blockade of cholinergic receptors, and inhibiting the N-methyl-D-aspartate receptor. This describes which of the following agents?
Rationale:
Amantadine increases dopamine release, blocks cholinergic receptors, and inhibits the N-methyl-D-aspartate (NMDA) receptor.
Amantadine's multifaceted mechanism makes it unique among Parkinson's medications. It enhances dopamine availability, reduces cholinergic activity, and antagonizes NMDA receptors, addressing both motor symptoms and dyskinesias. This combination distinguishes it from pure dopamine agonists or other drug classes, offering symptomatic relief through several neurotransmitter pathways.
B: Bromocriptine stimulates dopamine receptors directly without affecting cholinergic or NMDA receptors, making it a dopamine agonist but not matching the described combined actions.
C: Pramipexole acts solely as a dopamine receptor agonist, lacking effects on cholinergic blockade or NMDA receptor inhibition, thus not fitting the multi-target profile.
D: Rotigotine is a dopamine agonist delivered transdermally, without cholinergic receptor blockade or NMDA inhibition, differing fundamentally from the drug described.
A 45-year-old man with attention-deficit/hyperactivity disorder presents to his primary care physician for evaluation and treatment. Physical examination of the heart, lungs, and abdomen are within normal limits. The patient has begun on atomoxetine. Which of the following underlying disorders must the treating physician be aware of?
Rationale:
Atomoxetine requires caution in patients with bipolar disease due to the risk of inducing manic or hypomanic episodes. This medication’s noradrenergic effects can destabilize mood, necessitating careful psychiatric evaluation before and during treatment to monitor for mood swings or exacerbation of underlying mood disorders, particularly bipolar disorder.
A: Anxiety Anxiety is not primarily contraindicated with atomoxetine, though caution is advised. The main concern is mood destabilization, which is more characteristic of bipolar disorder rather than anxiety conditions.
C: Bleeding disorders Bleeding disorders do not have a direct relationship with atomoxetine use; the medication primarily affects neurotransmitter levels without known significant effects on coagulation or bleeding risk.
D: Chronic diarrhea Chronic diarrhea is unrelated to atomoxetine’s mechanism or side effect profile and does not require special consideration when prescribing this medication for ADHD.
A 35-year-old man who is an immigrant has been taking prazepam for anxiety for 10 years. This drug is not available in the United States, so he goes to see a physician about a drug that would be a good replacement. What might happen to this patient if he was unable to replace his prazepam and abruptly quit taking it?
Rationale:
Abruptly quitting prazepam can lead to convulsions and hallucinations. Prazepam is a long-acting benzodiazepine, and sudden discontinuation after prolonged use can cause severe withdrawal symptoms, including seizures and psychotic manifestations, due to abrupt GABA receptor downregulation and central nervous system hyperexcitability, making careful tapering essential to prevent these dangerous effects in patients dependent on the drug.
A: Adrenal insufficiency involves hormone deficiency unrelated to benzodiazepine withdrawal, which primarily affects the central nervous system rather than the endocrine system, making this an unlikely consequence.
C: Fever and muscle rigidity characterize neuroleptic malignant syndrome, a reaction to antipsychotics, not benzodiazepine withdrawal, which manifests mainly with neurological symptoms like seizures.
D: Myocardial infarction results from cardiac ischemia, not typically triggered by stopping benzodiazepines; withdrawal symptoms are neurological rather than cardiovascular in nature.